Older breast cancer patients see more complications with brachytherapy

heralded for its low complication rates—actually results in more complications than whole-breast radiation one year after treatment, Yale School of Medicine researchers report in the October issue of the Journal of Clinical Oncology.

The standard treatment for older women with early stage breast cancer includes breast-conserving surgery, typically followed by radiation therapy to reduce the risk of . Rather than irradiating larger areas of the breast, as in whole breast irradiation, brachytherapy temporarily implants radiation sources in catheters within the surgical site. This technique delivers larger and fewer directly to the , which results in a shortened treatment time and, proponents of the therapy believe, decreased toxicity to surrounding healthy tissue.

"This treatment method seems ideal in theory, but we found it concerning that such an important clinical decision that affects so many women was being made on the basis of theory, rather than scientific evidence," said the study's lead author Cary P. Gross, M.D., associate professor of internal medicine at Yale School of Medicine. "Despite the absence of large comparing these two treatments, brachytherapy has become increasingly popular, in part because of a theoretically lower rate of complications."

To test the theory, Gross' team studied a national sample of approximately 30,000 women with and found that 15.8% of women undergoing radiation therapy received brachytherapy in 2008-2009, up from less than 1% in 2000 and 10% in 2006. There was substantial variation in brachytherapy use across the country, ranging from less than 5% of patients in some areas to over 70% in others.

The team found that the use of brachytherapy was associated with a 16.9% higher rate of wound and skin complications in the year after treatment compared to whole breast irradiation. There was no significant difference in the rate of deep tissue or bone complications between the two treatments.

"This study highlights the importance of conducting comparative effectiveness research before a new treatment becomes widespread," said Gross, who is co-director of the Robert Wood Johnson Clinical Scholars Program at Yale. "Medicare is spending significantly more money to cover this treatment, which potentially exposes women to a higher risk of complications than the 'tried and true' whole ."

Related Stories

Breast cancer treatment procedure gives women more options

Nov 29, 2006

A new minimally invasive approach to partial breast irradiation provides another treatment option for women with breast cancer. The researchers presented their findings today at the annual meeting of the Radiological Society ...

Recommended for you

Decoding the emergence of metastatic cancer stem cells

7 hours ago

In the first study of its kind, Rice University researchers have mapped how information flows through the genetic circuits that cause cancer cells to become metastatic. The research reveals a common pattern ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.